 | ||
Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. It is currently being investigated as a treatment for relapsed or refractory peripheral T-cell lymphoma.
References
Alisertib Wikipedia(Text) CC BY-SA